Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
2024
2023
2022
2021
2020
2019
-
Nov 04,2024
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
Learn More
-
Oct 28,2024
HuidaGene Therapeutics to Attend BIO-Europe Fall 2024 to Expand Global Collaborations in Genome Medicines
Learn More
-
Oct 21,2024
HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations
Learn More
-
Oct 08,2024
HuidaGene Therapeutics Announces Eleven Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
Learn More
-
Sep 24,2024
HuidaGene Presents Late-Breaking Data at World Muscle Society 2024 Demonstrating HG302 CRISPR/hfCas12Max DNA-Editing Therapy for Duchenne Muscular Dystrophy to Support M.U.S.C.L.E. Clinical Trial
Learn More
-
Sep 09,2024
HuidaGene Therapeutics Announces the Appointment of Dr. Xin Zhang as Chief Operations Officer and Chief Medical Officer to Further Strengthen the Management Team
Learn More
-
Sep 02,2024
HuidaGene to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2024 Annual Meeting
Learn More
-
Jun 11,2024
NovoCrops and HuidaGene enter licensing partnership to expedite gene editing crop development
Learn More
-
May 31,2024
HuidaGene Therapeutics to Attend 2024 BIO International Convention in California for Actively Expanding Global Collaboration
Learn More